Suggestions
Christine Haller
Senior Vice President, Global Clinical Development at Ultragenyx Pharmaceutical Inc.
Professional Background
Christine Haller is an accomplished leader in the fields of medical toxicology, laboratory medicine, and dietary supplement pharmacology. With extensive expertise in drug safety and clinical development, Christine currently serves as the Senior Vice President of Global Clinical Development at Ultragenyx Pharmaceutical Inc. Her leadership and innovative contributions to the pharmaceutical industry have been vital in advancing the approach to rare disease treatments, ensuring patients receive safe and effective medication.
With a career that has spanned over two decades, Christine has built a robust portfolio at various prominent organizations within the healthcare sector. She has held several key positions at Ultragenyx Pharmaceutical Inc., initially joining as Vice President of Global Clinical Development and subsequently progressing to her current role as Senior Vice President. Under her guidance, the company has continued to innovate in the field of rare diseases, leveraging her deep understanding of drug safety and clinical methodologies to streamline development processes and enhance patient outcomes.
Before her tenure at Ultragenyx, Christine served as the Executive Group Medical Director of Clinical Sciences at BioMarin Pharmaceutical Inc., where she played a crucial role in the development and implementation of their clinical programs. Additionally, her experience as the Executive Medical Director of Global Safety at Amgen enabled her to hone her expertise in pharmacovigilance, focusing on patient safety and risk management for therapeutic products. Her earlier academic contributions as an Assistant Professor at UC San Francisco reflect her commitment to education and mentorship within the medical community.
Education and Achievements
Christine Haller's educational background is impressive and uniquely tailored to her career in medicine and pharmacology. She earned her Doctor of Medicine (MD) from the prestigious University of California, San Francisco - School of Medicine, where she cultivated her foundation in medical principles and practices. Further expanding her expertise, Christine achieved a Master of Science (MS) in Health and Medical Sciences from the University of California, Berkeley, where she delved into research and healthcare applications that continue to inform her work today.
Moreover, Christine completed her undergraduate studies in Chemical Engineering at the University of Utah. This interdisciplinary background in engineering has equipped her with critical thinking skills and a robust understanding of scientific processes that are beneficial in her roles in clinical development and safety assessments, particularly in drug formulation and toxicity analysis.
Christine's contributions to medical toxicology and drug safety have been recognized by her peers and industry leaders alike. Her extensive work has yielded meaningful advancements in understanding the toxicological profiles of various compounds, particularly in dietary supplements and novel therapeutics.
Achievements
Throughout her extensive career, Christine Haller has demonstrated unparalleled dedication and innovation in her field. Her leadership positions at Ultragenyx and Amgen have solidified her reputation as a pioneer of drug safety, risk management, and clinical research methodologies. She has successfully led multidisciplinary teams in developing clinical strategies that prioritize patient safety while advancing pharmacological research.
Christine's efforts in the pharmaceutical industry have collectively contributed to significant improvements in clinical outcomes for patients with rare diseases, ensuring that safety mechanisms are rigorously applied in both clinical trials and post-marketing surveillance. Her commitment to advancing medicine through safe and effective therapeutic options showcases her deep regard for the wellbeing of patients and the integrity of clinical practices.
Her two-fold expertise in both clinical medicine and toxicology positions her as a leading figure in the dialogue surrounding drug safety policies. Christine is a sought-after speaker at conferences and industry panels, where she shares her insights on pharmacovigilance and the complexities of medical toxicology in today’s pharmaceutical landscape.
Achievements
